Epidermal growth factor receptor (EGFR) mutational analysis is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify patients with certain activating mutations in the EGFR gene which are sensitive to tyrosine kinase inhibitors.

EGFR mutational analysis is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 01/01/2021+.

Item #	Length	Source of Standard	Year Implemented	Version Implemented	Year Retired	Version Retired
3939	1	NAACCR	2021	21

0	Normal EGFR negative, EGFR wild type Negative for mutations, no alterations, no mutations (somatic) identified, not present, not detected
1	Abnormal (mutated)/detected in exon(s) 18, 19, 20, and/or 21
2	Abnormal (mutated)/detected but not in exon(s) 18, 19, 20, and/or 21
4	Abnormal (mutated)/detected, NOS, exon(s) not specified
7	Test ordered, results not in chart
8	Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error.
9	Not documented in medical record EGFR not assessed or unknown if assessed
Blank	Diagnosis year is prior to 2021

Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.